Actualmente, solo hay tratamientos con tirzepatida en forma de inyeccin (Mounjaro) mientras que con semaglutida s hay medicamentos tanto en forma de inyeccin (Wegovy) como en pastillas (Rybelsus y Wegovy en pastillas)
This product is clearly labeled and distributed strictly as a Research Use Only (RUO) material and is not approved for human or veterinary use
According to the UK Summary of Product Characteristics (SmPC), liraglutide is not recommended in patients with inflammatory bowel disease and other severe gastrointestinal disease due to limited study data and the potential for gastrointestinal adverse effects
Mega Lifesciences Limited Inc
The key findings relevant to this question: No clinically relevant drug-metabolizing enzyme-mediated interactions have been reported for GLP-1 agonists Some transporters (OATP1B1/3, OAT3) showed inhibition with GLP-1 agonist treatment in vitro Significant changes in oral contraceptive and levothyroxine absorption were documented with tirzepatide and oral semaglutide GLP-1 agonists delay gastric emptying, which can alter absorption of co-administered oral medications Critically, no published study has examined the drug-drug interaction profile of two injectable GLP-1 agonists administered concurrently
This might have a bearing on the CAD development and its course